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I N T RODUC T I ON
Presynaptic voltage-gated Cav2.1 (P/Q-type), Cav2.2 
(N-type), and Cav2.3 (R-type) voltage-gated calcium 
channels (VGCCs) mediate nerve-evoked transmitter re-
lease. Their modulation by G protein–coupled receptors 
(GPCRs) is a key factor in controlling neuronal excit-
ability at central and peripheral synapses (Luebke et al., 
1993; Takahashi and Momiyama, 1993; Wu et al., 1998; 
Gasparini et al., 2001). Multiple GPCR-mediated path-
ways converge on VGCCs, but Cav2.3 channels are less 
susceptible to direct G protein  dimer modulation 
than Cav2.1 or Cav2.2 (Shekter et al., 1997), a finding at-
tributed to differences between the N terminus, domain I, 
and the I–II intracellular linker of Cav2.3 and Cav2.2 
channels (Stephens et al., 1998; Simen and Miller, 2000). 
Nevertheless, carbachol, somatostatin, ATP, and ade-
nosine inhibit exogenous Cav2.3 channels via endoge-
nous receptors in human embryonic kidney (HEK) cells 
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(Mehrke et al., 1997). Interestingly, carbachol, a musca-
rinic receptor agonist, stimulates or inhibits Cav2.3 cur-
rents by distinct signaling pathways in HEK cells (Bannister 
et al., 2004), whereas the D2 dopamine receptor agonist 
quinpirole (Page et al., 1998) and µ opioid receptor ago-
nist DAMGO (Ottolia et al., 1998) inhibit Cav2.3 currents 
in the Xenopus laevis oocyte system. Electrophysiological 
data suggest that baclofen, a derivative of -aminobutyric 
acid (GABA), inhibits R-type currents in the rat medial 
nucleus (Wu et al., 1998) and locus coeruleus neurons 
(Chieng and Bekkers, 1999).
VGCCs are associated with a wide range of patholo-
gies, including pain, and the value of selectively target-
ing Cav2 channels for neuropathic pain treatment is 
recognized (Altier et al., 2007; Pexton et al., 2011). We 
have shown that -conotoxin Vc1.1, a small venom pep-
tide from Conus victoriae, inhibits Cav2.2 channels via 
GABA type B (GABAB) receptors (GABABRs) in rodent 
dorsal root ganglion (DRG) neurons (Callaghan et al., 
2008; Callaghan and Adams, 2010) and the HEK expres-
sion system (Cuny et al., 2012). We also demonstrated 
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Neuronal Cav2.1 (P/Q-type), Cav2.2 (N-type), and Cav2.3 (R-type) calcium channels contribute to synaptic trans-
mission and are modulated through G protein–coupled receptor pathways. The analgesic -conotoxin Vc1.1 acts 
through -aminobutyric acid type B (GABAB) receptors (GABABRs) to inhibit Cav2.2 channels. We investigated 
GABABR-mediated modulation by Vc1.1, a cyclized form of Vc1.1 (c-Vc1.1), and the GABABR agonist baclofen of 
human Cav2.1 or Cav2.3 channels heterologously expressed in human embryonic kidney cells. 50 µM baclofen in-
hibited Cav2.1 and Cav2.3 channel Ba2+ currents by 40%, whereas c-Vc1.1 did not affect Cav2.1 but potently inhib-
ited Cav2.3, with a half-maximal inhibitory concentration of 300 pM. Depolarizing paired pulses revealed that 
75% of the baclofen inhibition of Cav2.1 was voltage dependent and could be relieved by strong depolarization. 
In contrast, baclofen or Vc1.1 inhibition of Cav2.3 channels was solely mediated through voltage-independent 
pathways that could be disrupted by pertussis toxin, guanosine 5-[-thio]diphosphate trilithium salt, or the GABABR 
antagonist CGP55845. Overexpression of the kinase c-Src significantly increased inhibition of Cav2.3 by c-Vc1.1. 
Conversely, coexpression of a catalytically inactive double mutant form of c-Src or pretreatment with a phosphory-
lated pp60c-Src peptide abolished the effect of c-Vc1.1. Site-directed mutational analyses of Cav2.3 demonstrated 
that tyrosines 1761 and 1765 within exon 37 are critical for inhibition of Cav2.3 by c-Vc1.1 and are involved in bac-
lofen inhibition of these channels. Remarkably, point mutations introducing specific c-Src phosphorylation sites 
into human Cav2.1 channels conferred c-Vc1.1 sensitivity. Our findings show that Vc1.1 inhibition of Cav2.3, which 
defines Cav2.3 channels as potential targets for analgesic -conotoxins, is caused by specific c-Src phosphorylation 
sites in the C terminus.
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were purchased from OriGene Technologies, Inc. Site-directed 
mutagenesis of the wild-type human Cav2.3d (1E-d) channel, result-
ing in 1E-d (Y1761F) or 1E-d (Y1765F), and site-directed mutagen-
esis of the wild-type human Cav2.1 (1A-5) channel, resulting in 1A-5 
(L1852T) or 1A-5 (Q1852E), was performed with the QuikChange 
II XL site-directed mutagenesis kit (Agilent Technologies), using 
the following oligonucleotides: Cav2.3(Y1761F)-for, GCATGTG-
GCCGCATCCATTTCACTGAGATGTATGAAATG; Cav2.3(Y1761F)-
rev, CATTTCATACATCTCAGTGAAATGGATGCGGCCACATGC; 
Cav2.3(Y1765F)-for, CATTACACTGAGATGTTTGAAATGCTGA-
CTCTC; Cav2.3(Y1765F)-rev, GAGAGTCAGCATTTCAAACATC-
TCAGTGTAATG; Cav2.1(L1852T)-for, GGCCGCATGCCTTACA-
CGGACATGTATCAGATG; Cav2.1(L1852T)-rev, CATCTGATAC-
ATGTCCGTGTAAGGCATGCGGCC; Cav2.1(Q1856E)-for, CTTA C-
C TG GACATGTATGAGATGCTGAGACACATGTC; Cav2.1(Q1856E)-
rev, GACATGTGTCTCAGCATCTCATACATGTCCAGGTAAG.
For all primers, sense and antisense orientations are denoted as 
“for” and “rev,” respectively. The names reflect the position of the 
tyrosine to be mutated to a phenylalanine (Cav2.3), leucine to thre-
onine (Cav2.1), or glutamine to glutamic acid (Cav2.1). All muta-
tions were verified by automated DNA sequencing (Australian 
Genome Research Facility).
HEK cells stably expressing Cav2.1 or Cav2.3c channels were 
transiently cotransfected with plasmid cDNAs encoding human 
GABABR1 (RefSeq accession no. NM_001470; 3 µg; OriGene 
Technologies, Inc.), human GABABR2 (RefSeq accession no. 
NM_005458; 3 µg; OriGene Technologies, Inc.), and enhanced 
green fluorescent protein (eGFP) reporter gene construct (1 µg; 
provided by J.W. Lynch, The University of Queensland, Brisbane, 
Australia), using the calcium phosphate precipitation method 
(Jordan et al., 1996). In separate experiments, pRC-CMV/Src en-
coding wild-type mouse c-Src or pRC-CMV/Src(K295R/Y527F) 
double mutant mouse c-Src cDNA (provided by J. Ulrich, Univer-
sity of Iowa, Iowa City, IA) was also included in the above transfection 
mixture. The K295R mutation in the ATP-binding site inactivates 
the kinase, whereas the Y527F mutation abolishes intramolecular 
interactions between the C-terminal tail and the SH2 domain (Gao 
et al., 1997).
HEK-293T cells were transiently cotransfected with plasmid 
cDNAs encoding human Cav2.1 channel transcript variant 5 (5 µg) 
or wild-type or mutant human Cav2.3d channels (5 µg), human 
2b-1 (5 µg) and human 3 (5 µg) auxiliary subunits, human 
GABABR1 (3 µg), human GABABR2 (3 µg), and eGFP (1 µg). In a 
separate series of experiments, HEK-293T cells were transiently 
cotransfected with plasmid cDNAs encoding rabbit Cav2.1 channel 
(RefSeq accession no. NM_001101693; 5 µg; provided by F. Meunier, 
The University of Queensland, St. Lucia, Australia), rat 2-1 (5 µg; 
provided by G.W. Zamponi, University of Calgary, Calgary, Canada) 
and rat 3 (5 µg; provided by D. Lipscombe, Brown University, 
Providence, RI) auxiliary subunits; human GABABR1 (3 µg) and 
human GABABR2 (3 µg); and eGFP (1 µg). After transfection, cells 
were plated on glass coverslips and incubated at 37°C in 5% CO2 
for 6 h. Transfection medium was then replaced with culture me-
dium, and cells were incubated at 30°C in 5% CO2.
Electrophysiology
Experiments were performed 3–5 d after transfection, using the 
whole-cell patch-clamp technique. Currents through calcium 
channels were recorded using barium (Ba2+) as the charge car-
rier. Cells expressing the proteins of interest were superfused with 
a solution containing (mM): 110 NaCl, 10 BaCl2, 1 MgCl2, 5 CsCl, 
30 TEA-Cl, 10 d-glucose, and 10 HEPES, pH 7.4 with TEA-OH, at 
600 µl/min. Fire-polished borosilicate patch pipettes with tip 
resistance values of 2–3 MΩ were filled with an intracellular solu-
tion containing (mM): 125 K-gluconate, 2 MgCl2, 5 EGTA, 5 NaCl, 
4 MgATP, and 10 HEPES, pH 7.25 with CsOH. In a series of ex-
periments, EGTA was included in the intracellular solution at a 
that Vc1.1 can be used as an analgesic in rat models of 
neuropathic pain (Klimis et al., 2011). Cav2.3 channels 
are also present in various nociceptors (Fang et al., 
2007, 2010) and contribute to pain behavior control by 
spinal and supraspinal mechanisms (Saegusa et al., 
2000; Terashima et al., 2013). However, Cav2.3 modula-
tion via GABABRs is incompletely characterized and has 
not been reconstituted in any heterologous expression 
system. Moreover, few drugs or toxins have specific Cav2.3 
inhibitory effects (Schneider et al., 2013).
In this study, we hypothesized that -conotoxin Vc1.1 
can modulate Cav2.1 and Cav2.3 channels via GABABR 
activation. We designed experiments to examine the 
mechanisms of VGCC Ba2+ current (IBa) inhibition by 
baclofen and Vc1.1, with emphasis on voltage-dependent 
(VD) and voltage-independent (VI) pathways, which 
may be present in these cells. Our data show that Vc1.1 
only inhibits Cav2.3 channels, despite baclofen efficiently 
inhibiting both Cav2.1 and Cav2.3 channels. Using site-
directed mutagenesis in combination with functional 
expression in HEK cells, we demonstrate that c-Src phos-
phorylation of specific tyrosine residues in the 1 sub-
unit C terminus is sufficient to mediate Vc1.1 inhibition 
of Cav2.3 channels. A preliminary report of these results, 
in part, has been presented in abstract form (Berecki, 
G., J.R. McArthur, and D.J. Adams. 2013. Australian 
Neuroscience Society Inc. 33rd Annual Meeting. Abstr. 
ORAL-03-03).
MAT E R I A L S  AND  M E THOD S
Cell culture, clones, and transfections
HEK cells containing the SV40 large T antigen (HEK-293T) were 
cultured at 37°C in 5% CO2 in Dulbecco’s modified Eagle’s me-
dium (Invitrogen) supplemented with 10% (vol/vol) fetal bovine 
serum (Invitrogen), 50 IU/ml penicillin, and 50 µg/ml strep-
tomycin (Invitrogen). HEK-293 cells, stably expressing human 
Cav2.1 (P/Q-type) channel 1A-2 splice variant (GenBank acces-
sion no. AF004883) or human Cav2.3c (R-type) channel 1E-3 
splice variant (also called 1E-c; GenBank accession no. L29385), 
were obtained from Merck and cultured according to procedures 
described previously (Dai et al., 2008). Both cell lines express 
human 2b-1 (GenBank accession no. M76559) and human 3a 
(RefSeq accession no. NM_000725) auxiliary subunits, and the 
human KCNJ4 (Kir2.3; GenBank accession no. U07364) channel 
(Dai et al., 2008).
The human Cav2.1 (P/Q-type) channel, 1A, transcript variant 
5 (RefSeq accession no. NM_001174080), cloned into pCMV plas-
mid, was provided by J. Striessnig (University of Innsbruck, Inns-
bruck, Austria). The human Cav2.3d (R-type) channel (fetal brain 
1E-d, splice variant L27745) was provided by T. Schneider (Univer-
sity of Cologne, Cologne, Germany). The wild-type human Cav2.3c 
(1E-c) channel (GenBank accession no. L29385) and mutant 
Cav2.3c channels, 1E-c (Y1761F) and 1E-c (Y1765F), all cloned 
into pCDNA3.1 vectors, were purchased from GenScript USA Inc. 
The 1E-d splice variant is identical in amino acid sequence to 1E-c, 
except for a 43–amino acid segment (insert III or exon 46) at the 
C terminus of the 1E-d channel (Pereverzev et al., 2002). Human 
2b-1 (RefSeq accession no. NM_000722) and human 3 channel 
subunits, transcript variant 1 (RefSeq accession no. NM_000725), 
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acid hydrochloride (CGP55845) and pp60c-Src peptide (521–
533) were purchased from Tocris Bioscience.
c-Src phosphorylation site prediction
A publicly available catalog of phosphorylation motifs (http://
www.hprd.org/PhosphoMotif_finder; Amanchy et al., 2007) was 
used to identify Src kinase substrate motifs within Cav2.1 and 
Cav2.3 C-terminal regions corresponding to exon 37 (e37) of 
Cav2.2 channel. This catalog does not use algorithms or computa-
tional strategies to predict phosphorylation but reports the pres-
ence of any literature-derived motifs.
Curve fitting and statistical analysis
Data analysis was performed in Clampfit 9.2 (Molecular Devices) 
and Origin 9.0 (Microcal Software Inc.). The voltage dependence 
of IBa activation was determined from I-V curves fitted to the fol-
lowing transform of a Boltzmann function: IBa = Gmax(V  Vrev)/
{1 + exp[(V  V0.5,act)/k]}, where Vrev is the extrapolated reversal po-
tential, V is the membrane potential, IBa is the peak current elic-
ited by the voltage pulse, Gmax is the maximum conductance, 
V0.5,act is the voltage for half-maximal current activation, and k is 
the slope factor (Favre et al., 1995). Current amplitudes obtained 
in the presence of a compound (I) were normalized to current 
amplitudes obtained under control conditions (I0). Concentra-
tion–response curves were obtained by plotting averaged relative 
peak current amplitude (I/I0) against compound concentration 
and fitting the Hill equation I = I0{[D]h/(IC50h + [D]h)} to result-
ing data, where I0 is the maximum peak current amplitude, [D] is 
the concentration of the compound (drug), IC50 is the half-maximal 
inhibitory concentration, and h is the Hill coefficient (slope). 
Concentration–response curves are interpreted as functional re-
sponses by a ligand (baclofen or c-Vc1.1) against a change in ligand 
concentration. Results shown in Fig. 2 (B and C) and Table 2 were 
obtained by applying increasing concentrations of baclofen to the 
extracellular solution. Because baclofen inhibition of Cav2.3 chan-
nels is irreversible, these experiments do not represent equilibrium 
steady-state measurements (Christopoulos and Kenakin, 2002).
Data are mean ± SEM (n, number of experiments). Statistical 
analyses were performed in Sigma Plot 11.0 (Systat Software, Inc.) 
using Student’s t test for two groups or one-way ANOVA with Bon-
ferroni post-hoc testing for multiple comparisons. When one-way 
ANOVA failed, Kruskal–Wallis one-way ANOVA on ranks with 
Tukey test for multiple comparisons was used. Differences were 
considered statistically significant at P < 0.05.
Online supplemental material
Table S1 shows the parameters of the Boltzmann fits to I-V and 
G-V curves in Cav2.1/GABABR cells in the presence of 0.5 or 10 mM 
EGTA in the intracellular recording solution. Fig. S1 shows the 
voltage dependence of baclofen inhibition of Cav2.3d channels in 
the presence of 0.5 or 10 mM EGTA in the intracellular recording 
solution. Whole-cell IBa was recorded from HEK cells transiently 
coexpressing wild-type Cav2.3d or mutant Cav2.3d (Y1765F) chan-
nels and GABABRs. The online supplemental material is available 
at http://www.jgp.org/cgi/content/full/jgp.201311104/DC1.
R E S U L T S
Differential inhibition of Cav2.3 and Cav2.1 channels 
by -conotoxin Vc1.1 via G protein–coupled GABABRs
We investigated VGCC modulation by baclofen and 
-conotoxin Vc1.1 in HEK cells stably expressing Cav2.1 
(1A-2) or Cav2.3c (1E-c) channels and transiently ex-
pressing GABABRs (Cav2.1/GABABR cells or Cav2.3/
GABABR cells, respectively). Fig. 1 (A–C) shows typical 
concentration of 0.5 or 10 mM. GTP was not used in the intracel-
lular solution to prevent IBa rundown caused by activation of sig-
naling pathways when the whole-cell recording configuration 
was established (Raingo et al., 2007). To minimize endogenous 
currents, the osmolarity of solutions was adjusted with sucrose 
(310-mOsm extracellular, slightly hypertonic with respect to the 
295-mOsm intracellular solution).
Electrophysiological recordings were performed at room tem-
perature (23–25°C) using Multiclamp 700B amplifiers (Molecular 
Devices) controlled by Clampex 9.2/DigiData 1332 acquisition 
systems. I-V relationships were recorded from a holding potential 
(HP) of 80 mV using 100-ms depolarizations from 45 to +50 mV, 
in 5-mV increments. Peak IBa was measured for each step and nor-
malized to the cell’s maximal current. Normalized currents were 
averaged across cells and plotted (mean ± SEM) as a function of 
voltage. Test depolarizations to 10 mV (in cells coexpressing 
Cav2.3 channels and GABABRs) or 15 mV (in cells coexpressing 
Cav2.1 channels and GABABRs) of 150-ms duration were applied 
at a frequency of 0.1 Hz from an HP of 80 mV, where IBa was 
evaluated in the absence and presence of various compounds.
VD relief of the inhibition was assessed from an HP of 80 mV, 
using a protocol with a 20-ms prepulse to +80 mV, a 5-ms inter-
pulse to 80 mV, and a 40-ms test pulse to +10 mV. The percent-
age of IBa inhibited in the absence of a prepulse (PP IBa) or 
presence of a +80-mV prepulse (+PP IBa) was determined accord-
ing to [(I0PP  IPP)/I0PP] × 100, or [(I0+PP  I+PP)/I0+PP] × 100, 
respectively, where I0+PP and I0PP represent current amplitudes 
(controls) obtained with or without a prepulse in the absence of 
a compound, respectively. I0PP was normalized to I0+PP. I+PP and 
IPP represent current amplitudes obtained with or without a pre-
pulse in the presence of a compound, respectively. The VI frac-
tion was defined as (+PP IBa) × 100/(PP IBa), whereas the VD 
fraction was calculated as (PP IBa)  VI.
Membrane currents were filtered at 3 kHz and sampled at 
10 kHz. Leak and capacitive currents were subtracted using a P/4 
pulse protocol. Peptides and various drugs were prepared from 
stock solutions, diluted to appropriate final concentration, and 
applied via perfusion in the bath solution. Data were stored digi-
tally on a computer for further analysis. Current densities were 
calculated by dividing the normalized current amplitude by the 
cell capacitance measured at the start of each experiment.
In successive transfections, the magnitude of baclofen inhibi-
tion of IBa was routinely tested in HEK cells stably expressing 
Cav2.1 or Cav2.3 channels and coexpressing GABABRs. In 5% 
of all cells tested, IBa inhibition by baclofen was ≤25%. In such 
cases, the results were not included in the analysis or the experi-
ment was discontinued. When evaluating the Vc1.1 concentration 
dependence of IBa inhibition, only a maximum of three differ-
ent Vc1.1 concentrations per cell were tested because of the rela-
tively long time needed to reach maximum inhibition with each 
Vc1.1 concentration.
Peptides, chemicals, and drugs
-Conotoxins Vc1.1, cyclized-Vc1.1 (c-Vc1.1), and PeIA were syn-
thesized as described previously (Clark et al., 2006, 2010; Daly 
et al., 2011). Synthetic Vc1.1 and PeIA are 16–amino acid residue 
peptides with a characteristic helical region and two disulfide 
bonds in a I–III, II–IV arrangement (Clark et al., 2006, 2010; Daly 
et al., 2011). c-Vc1.1 exhibits better properties than the linear 
Vc1.1 (also known as ACV1), including high chemical stability, 
resistance to cleavage by proteases, and improved potency to in-
hibit N-type VGCCs (Clark et al., 2010). Most data on -conotoxin 
effects on various Cav2 channels were obtained using c-Vc1.1, un-
less otherwise noted. GABA, baclofen, guanosine 5-[-thio]di-
phosphate trilithium salt (GDP--S), and pertussis toxin (PTX) 
were purchased from Sigma-Aldrich. (2S)-3-[[(1S)-1-(3,4-dichlo-
rophenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl) phosphinic 
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GABABR and Cav2.3/GABABR cells and exhibited IC50 
values similar to those obtained with baclofen (Table 2). 
The c-Vc1.1 concentration dependence of IBa inhibition 
in Cav2.3/GABABR cells (Fig. 2 F) resulted in IC50 and 
Hill coefficient values of 290 ± 0.8 pM and 0.61 ± 0.1, re-
spectively, and defined c-Vc1.1 as a potent Cav2.3 chan-
nel inhibitor (Table 2). Fig. 2 (A and C) and Table 1 
summarize the average IBa inhibition by baclofen, GABA, 
Vc1.1, c-Vc1.1, and PeIA in the absence and presence of 
GABABRs. These results demonstrate that GABABR ex-
pression is needed for baclofen to inhibit Cav2.1 and 
Cav2.3 channels, and for c-Vc1.1 to inhibit Cav2.3 chan-
nels. Moreover, the decreased response to baclofen 
after c-Vc1.1’s effect is consistent with an overlap be-
tween the intracellular signaling mechanisms induced 
by these two compounds (Figs. 1 B and 2 E).
Voltage dependence of GABABR-mediated inhibition 
of Cav2.1 and Cav2.3 channels
Direct VGCC inhibition by G protein–dependent inhib-
itory pathways involves VD G binding to the pore-
forming subunit (Bean, 1989; Kasai and Aosaki, 1989; 
Lipscombe et al., 1989). I-V relationships were recorded 
examples of depolarization-activated whole-cell IBa in 
the absence or presence of 200 nM c-Vc1.1 or 50 µM 
baclofen. In Cav2.1/GABABR cells, c-Vc1.1 did not mod-
ulate IBa but inhibited IBa in Cav2.3/GABABR cells. The 
effect of c-Vc1.1 developed relatively slowly, reached 
maximum inhibition 3–7 min after the response started, 
and was irreversible (Fig. 1 B). The “linear” -conotoxin 
Vc1.1 and -conotoxin PeIA also inhibited depolariza-
tion-activated IBa in Cav2.3/GABABR cells (Table 1).
These peptides have been shown to selectively inhibit 
high voltage–activated N-type calcium channels by act-
ing as G protein–coupled GABABR agonists in rat DRG 
neurons (Callaghan et al., 2008; Daly et al., 2011). 
Cav2.1/GABABR or Cav2.3/GABABR cells typically re-
sponded to baclofen, with relatively fast IBa inhibition 
that was completely reversible or weakly reversible/ir-
reversible, respectively (Fig. 1, A and C, and Table 1). In 
most experiments, applying baclofen after c-Vc1.1 ex-
posure further suppressed a small fraction (<10%) of 
IBa in Cav2.3/GABABR cells. We determined the ba-
clofen concentration dependence of IBa inhibition for 
Cav2.1 and Cav2.3 channels (Fig. 2, B and D), resulting 
in relationships described by the Hill equation (Table 2).
 50 µM GABA also inhibited 40% of IBa in Cav2.1/
Figure 1. Effects of -conotoxin c-Vc1.1 and baclofen 
(bac) on stably expressed human Cav2.1 (1A-2) or human 
Cav2.3c (1E-c) channels in the presence of transiently ex-
pressed human GABABR subunits R1 and R2 (GABABR). 
(A and B) 50 µM baclofen inhibits Cav2.1 or Cav2.3c chan-
nel currents, whereas 200 nM c-Vc1.1 only inhibits Cav2.3c 
currents. Bars indicate c-Vc1.1 or baclofen application. 
IBa was evoked by 150-ms depolarizations to 10 mV (Cav2.3c) 
or 15 mV (Cav2.1), applied every 10 s from an HP of 80 mV 
(voltage inset). Peak current amplitudes were plotted as 
a function of time. Representative IBa traces (right) are 
shown at the times indicated by lowercase letters. Hori-
zontal dotted line represents zero-current level. Note that 
Cav2.1 current inhibition by baclofen is reversible on wash-
out (A), whereas baclofen or c-Vc1.1 irreversibly inhibits 
Cav2.3c currents (B). (C) 50 µM baclofen inhibits IBa in 
Cav2.3/GABABR cells. Experimental procedures are simi-
lar to those in A or B.
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from 6.18 ± 0.3 mV (n = 8; control) to 7.40 ± 0.58 mV (n = 
8; baclofen), but the difference was not statistically 
significant (P = 0.083) in Cav2.1/GABABR cells. How-
ever, it should be noted that the inhibition of Cav2.1/
GABABR cells by baclofen (31.1 ± 2.6%) is slightly less 
than the inhibition shown in Fig. 2 A and Table 1. This 
is probably because of spontaneous IBa recovery from 
inhibition that occurred even in the continuous pres-
ence of baclofen and could cause the underestimation 
of the V0.5,act positive shift in these experiments. To re-
duce the contribution of recovery in this process, we 
in the absence and presence of baclofen in Cav2.1/
GABABR cells and Cav2.3/GABABR cells, or c-Vc1.1 in 
Cav2.3/GABABR cells. The biophysical properties of ion 
permeation through Cav2.1 and Cav2.3 channels stably 
expressed in HEK cells have been characterized previously 
(Dai et al., 2008). We evaluated any depolarizing shift in 
the midpoint of activation (V0.5,act) of these channels, 
which may indicate the presence of direct G modula-
tion, by fitting I-V relationships to a modified Boltzmann 
function (see Materials and methods; Fig. 3 A). Fits of 
the normalized I-Vs revealed that V0.5,act shifted slightly 
TA B l e  1
Summary of IBa inhibition by baclofen, GABA, or -conotoxins in the presence or absence of GABABRs in HEK cells stably expressing human Cav2.1 or 
Cav2.3c channels
Agonist IBa inhibition (%)
Cav2.1 and GABABR Cav2.1 alone Cav2.3c and GABABR Cav2.3c alone
Baclofen (50 µM) 39.9 ± 2.6 (17) 0 (5) 39.5 ± 4.3 (11) 0 (6)
GABA (50 µM) 38.4 ± 2.7 (7) ND 39.3 ± 4.1 (9) ND
Vc1.1 (200 nM) 0 (9) ND 25.5 ± 4.2 (9) ND
c-Vc1.1 (200 nM) 0 (10) 0 (6) 34.8 ± 2.9 (16) 0 (5)
PeIA (200 nM) 0 (3) ND 27.0 ± 3.0 (3) ND
Values represent mean ± SEM; n, number of experiments in parentheses; ND, not determined.
Figure 2. Stably expressed human Cav2.1 (1A-2) or human 
Cav2.3c (1E-c) channel inhibition by baclofen (bac) and 
-conotoxin Vc1.1 in the absence and presence of transiently 
expressed human GABABR. (A and C) Bar graphs show-
ing average IBa inhibition through Cav2.1 (A) or Cav2.3c 
(C) channels by 50 µM baclofen, 200 nM Vc1.1, or 200 nM 
c-Vc1.1. Numbers in parentheses indicate the number of 
experiments. (E) Average IBa inhibited by 50 µM baclofen 
applied before or after 200 nM c-Vc1.1; “before c-Vc1.1” 
data are replotted from C. (B, D, and F) Concentration-
dependent inhibition of IBa through Cav2.1 and Cav2.3c 
channels by baclofen (B and D) and Cav2.3c channels by 
c-Vc1.1 (F). See IC50 values in Table 2.
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In Cav2.3/GABABR cells, the V0.5,act values were 3.44 ± 
0.67 mV (n = 8) in the presence of baclofen and 0.44 ± 
0.46 mV (n = 7) for c-Vc1.1 compared with 0.67 ± 0.24 mV 
(n = 15; control). In these experiments, baclofen caused 
a significant hyperpolarizing shift of V0.5,act (P < 0.001 vs. 
control; one-way ANOVA). However, V0.5,act was not al-
tered by c-Vc1.1 (P = 0.223).
also investigated baclofen inhibition of IBa in Cav2.1/
GABABR cells, evoked by voltage ramps. To assess any 
effect of divalent cation buffering on I-V relationships, 
we included 0.5 or 10 mM EGTA in the intracellular 
solution (Fig. 4 and Table S1). Voltage ramps in the ab-
sence and presence of baclofen resulted in V0.5,act values 
similar to those obtained with voltage steps (Fig. 3 A). 
TA B l e  2
Summary of half-maximal inhibitory concentration (IC50) and Hill slope values in HEK cells stably expressing human Cav2.1 or Cav2.3c channels and 
transiently coexpressing GABABRs
Agonist Cav2.1 and GABABR Cav2.3c and GABABR
IC50 Hill slope IC50 Hill slope
nM nM
Baclofen 470 ± 34 (5) 0.73 ± 0.05 330 ± 72 (7) 0.75 ± 0.14
GABA 388 ± 17 (4) 0.76 ± 0.20 328 ± 102 (4) 0.75 ± 0.24
c-Vc1.1 — — 0.29 ± 0.08 (4–7)a 0.61 ± 0.14
Values represent mean ± SEM; n, number of experiments in parentheses; see details of the fitting procedure in Materials and methods.
aEach data point (Fig. 2 F) was obtained from four to seven individual experiments.
Figure 3. Voltage dependence of Cav2.1 (1A-2) 
and stably expressed Cav2.3c channel inhibition 
via GABABR activation. (A) I-V relationships 
in Cav2.1/GABABR cells (left) in the absence 
(control) and presence of 50 µM baclofen, and 
in Cav2.3/GABABR cells (right) in the absence 
(control) or presence of 50 µM baclofen or 200 nM 
c-Vc1.1. (Insets) Voltage protocol and represen-
tative normalized current traces (only 23 ms of 
the 100-ms traces are shown). See Table S1 for 
V0.5,act values. (B) Cav2.1 channel inhibition via 
GABABR is VD, whereas that of Cav2.3c is VI. 
Representative 15-mV depolarization-activated 
inward IBa from Cav2.1/GABABR cells (top) in 
the absence (control) or presence of 50 µM ba-
clofen, without (PP) or after the application 
of a depolarizing prepulse to +80 mV (+PP). 
(Bottom) Representative 10-mV depolarization-
activated IBa from Cav2.3/GABABR cells in the 
absence (control) or presence of 50 µM baclofen 
or 200 nM c-Vc1.1. Dotted lines indicate zero-
current level. The voltage protocol (top inset) 
is described in Materials and methods. (Right) 
Summary of IBa inhibition in the absence or pres-
ence of a prepulse. Data are mean ± SEM (paired 
Student’s t test; *, P < 0.001 vs. control [PP] in 
Cav2.1/GABABR cells). The number of experi-
ments is in parentheses. VD, voltage dependent; 
VI, voltage independent.
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c-Vc1.1 inhibition of Cav2.3 channels involves Gi/o 
subunits and c-Src kinase
We evaluated the VI pathway leading to Cav2.3 channel 
modulation by determining the fraction of IBa that could 
be inhibited under various experimental conditions 
(Fig. 5). In HEK cells stably expressing Cav2.3c chan-
nels (Cav2.3 cells) or Cav2.3 cells coexpressing GABABR 
R2 subunits, neither 200 nM c-Vc1.1 nor 50 µM ba-
clofen inhibits IBa, indicating that a fully functional 
GABABR heterodimer is needed for proper signaling. 
In Cav2.3/GABABR cells, the selective GABABR antago-
nist CGP55845 (1 µM) did not change IBa amplitude or 
kinetics but strongly antagonized IBa inhibition by 
c-Vc1.1 and reduced the effect of baclofen by 60% 
compared with control. This confirmed that GABABR 
needed to be activated for c-Vc1.1 and baclofen inhibi-
tory effects to occur. When the hydrolysis-resistant GDP 
analogue GDP--S (500 µM) was added to the intracellu-
lar recording solution, Vc1.1 and baclofen inhibitory ef-
fects were almost identically reduced. Overnight treatment 
We evaluated if baclofen inhibition of IBa in Cav2.1/
GABABR and Cav2.3/GABABR cells, and c-Vc1.1 inhibi-
tion of IBa in Cav2.3/GABABR cells, could be reversed by 
strong depolarization. A +80-mV prepulse of 20-ms dura-
tion was applied before the test pulse to relieve any 
VD component of G protein–mediated IBa inhibition 
(Fig. 3 B). In both cells, shortening (10 ms) or prolong-
ing (50 ms) the prepulse or interpulse (10 ms) did not 
change IBa facilitation. Applying +120-mV prepulses only 
added 5% facilitation in Cav2.1/GABABR cells, without 
changing IBa relief with Cav2.3/GABABR cells (not de-
picted). The inhibitory effect of baclofen was associated 
with a large (73 ± 4%) VD component in Cav2.1/GABABR 
cells. In contrast, the effect of baclofen and Vc1.1 was 
solely mediated by a VI pathway in Cav2.3/GABABR cells, 
which clearly indicates that intracellular signaling does 
not involve the classical G protein  dimer (G) bind-
ing to the pore-forming Cav2.3 channel subunit. Alter-
natively, G could bind with high affinity to the Cav2.3 
channel in a VI manner.
Figure 4. Effects of baclofen on stably expressed human Cav2.1 (1A-2) channels in the presence of transiently expressed human GABABRs 
(Cav2.1/GABABR cells). (A) Baclofen-inhibition of IBa in the presence of 0.5 mM EGTA in the intracellular recording solution. 50 µM 
baclofen reversibly inhibited IBa by 38.5 ± 3.9% (n = 5). (Left) Representative currents in the absence (control) and presence of bac-
lofen, elicited by voltage ramps to +50 mV from an HP of 80 mV at 0.1 Hz. Dotted line represents zero-current level. (Middle) I-V 
relationships in the absence and presence of baclofen. Current amplitudes were determined from voltage ramps at selected membrane 
potentials (Vm). Solid lines are fits of the modified Boltzmann equation to normalized I-V relationships (see Materials and methods). (Right) 
Voltage dependence of activation determined from G-V relationships. Relative conductance (G/Gmax) was calculated as IBa/(Vm  Vrev), 
where Vrev is the reversal potential of the whole-cell current and plotted as a function of Vm. The normalized G-V relationships were 
fitted with a Boltzmann function, G = Gmax/(1 + exp((V0.5,act  Vm)/k)), where V0.5,act is the potential at which the conductance is half-
maximally activated, and k is the slope factor. (B) Similar experimental procedures and data representation as shown in A, with 10 mM 
EGTA in the intracellular recording solution. Baclofen reversibly inhibited IBa by 41.8 ± 4.7% (n = 6). See Table S1 for V0.5,act (voltage for 
half-maximal current activation) and k (slope factor) values resulting from experiments shown in A and B.
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Tyrosines 1761 and 1765 are needed in the C terminus  
for c-Src phosphorylation of Cav2.3 channels
Alternative splicing of Cav2.1, Cav2.2, and Cav2.3 genes 
creates channels with distinct kinetic, pharmacological, 
and modulatory properties (Bourinet et al., 1999; Bell 
et al., 2004; Fang et al., 2007; Gray et al., 2007). It has 
been reported that GPCR-mediated inhibition of the 
nociceptor-specific Cav2.2[e37a] channel occurred via 
VD and VI pathways. In HEK cells coexpressing GABABRs 
and Cav2.2[e37a] channels, the baclofen-induced VI 
component required a tyrosine (Y) residue in e37a to 
be phosphorylated (Raingo et al., 2007).
Alignment of the Cav2.2 channel e37a and e37b re-
gions with the corresponding e37 regions in human 
Cav2.3c, Cav2.3d, and Cav2.1 (1A-2 or 1A-5), and rabbit 
Cav2.1 channels, indicated a degree of structural con-
servation and the presence of tyrosine kinase consensus 
sites (Fig. 7 A). We hypothesized that Y residues within 
e37 at the proximal C terminus in Cav2.3 channels could 
serve as substrates for phosphorylation by c-Src. Using a 
publicly available catalog of phosphorylation motifs 
(Amanchy et al., 2007), we identified putative c-Src kinase 
phosphorylation sites in human Cav2.3 and rabbit Cav2.1, 
but not in human Cav2.1 channels. In both human Cav2.3c 
and Cav2.3d splice variants, the Y1761 and Y1675 (as num-
bered in GenBank accession no. L29385) are followed 
by a threonine (T) or glutamic acid (E), respectively, as 
are potential substrates for Src kinases. Remarkably, in 
rabbit Cav2.1, the second Y residue followed by alanine 
(A) also represents a Src motif described in the litera-
ture. In contrast, in the human Cav2.1 splice variants 
1A-2 or 1A-5, the consensus Y1851 and Y1855 residues (as 
numbered in RefSeq accession no. NM_001174080) lack 
the neighboring amino acids that are needed to generate 
known Src kinase substrates for phosphorylation (Amanchy 
et al., 2007).
We conducted a structure–function study in the e37 
region to identify the amino acid residues responsible 
for the different sensitivity to c-Vc1.1. We also tested 
their contribution to c-Src–mediated inhibition in HEK 
cells transiently coexpressing GABABRs and transiently 
expressing Cav2.3c or Cav2.3d splice variants, or human 
or rabbit Cav2.1 channels. In patch-clamp experiments, 
200 nM c-Vc1.1 inhibited human Cav2.3c and Cav2.3d 
channels but did not affect human Cav2.1 (1A-5) (Fig. 7 B 
and Table 3). This confirmed previous results in HEK 
cells stably expressing Cav2.1 (1A-2) or Cav2.3c channels 
in the presence of GABABRs (Figs. 1 and 2). In all ex-
periments, 50 µM baclofen inhibited IBa. As predicted, 
c-Vc1.1 also inhibited rabbit Cav2.1 channels, likely be-
cause of the presence of a putative c-Src phosphoryla-
tion site in the C terminus (Fig. 7 A).
Mutational analyses of the e37 region in the proximal 
C termini of Cav2.3d or Cav2.3c demonstrated that the 
Y1761F mutation completely abolished c-Vc1.1 inhibi-
tion of IBa, and the Y1765F mutation significantly reduced 
with 1 µg/ml PTX abolished c-Vc1.1 and baclofen inhibi-
tory pathway(s) in Cav2.3/GABABR cells, suggesting that 
the effects were mediated by Gi and/or Go proteins.
We previously showed that Vc1.1 inhibition of N-type 
(Cav2.2) calcium channel currents can be blocked by a 
phosphorylated synthetic pp60c-Src peptide (Callaghan 
et al., 2008). This is probably a result of pp60c-Src bind-
ing to the SH2 domain of native c-Src protein in rat 
DRG neurons. Therefore, we examined in more detail 
the role of c-Src in the GABABR-mediated Cav2.1 or Cav2.3 
channel inhibition by baclofen and c-Vc1.1 in the HEK 
expression system (Fig. 6). We changed endogenous 
HEK cell c-Src protein levels (Luttrell et al., 1999) by 
including cDNAs of wild-type or mutant c-Src in our 
expression system. In Cav2.1/GABABR cells, wild-type 
c-Src protein overexpression or inclusion of the pp60c-
Src peptide (50 µM) in the intracellular solution did 
not affect baclofen inhibition of IBa. However, in Cav2.3/
GABABR cells, wild-type c-Src protein overexpression 
dramatically increased the fraction of IBa inhibited by 
c-Vc1.1 compared with control.
To further evaluate the effect of c-Src on Cav2.3/GABABR 
cells, we overexpressed the K295R/Y527F c-Src dou-
ble mutant, which is kinase inactive and functions as a 
dominant-negative inhibitor of wild-type c-Src (Gao et al., 
1997). This construct reduced the effect of baclofen 
compared with control and abolished c-Vc1.1’s inhibi-
tory effect. The effect of K295R/Y527F c-Src was reca-
pitulated with the pp60c-Src peptide, suggesting that 
c-Src kinase activity is needed for VI inhibition of IBa by 
c-Vc1.1 and baclofen (Fig. 6, A and B).
Figure 5. c-Vc1.1 and baclofen inhibit stably expressed Cav2.3c 
calcium channels via G protein–coupled GABABRs. Neither com-
pound inhibits IBa in the absence of GABABRs (see also Fig. 2 C) 
or the absence of GABABR R1 subunits. 1 µM CGP55845 or 500 µM 
GDP--S significantly reduces c-Vc1.1 and baclofen responses, 
respectively. A 24-h pretreatment with 1 µg/ml PTX abolishes 
the effect of c-Vc1.1 or baclofen. Data are mean ± SEM (one-
way ANOVA; *, P < 0.001 vs. controls; Cav2.3/GABABR cells with 
c-Vc1.1 or baclofen, respectively).
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the c-Vc1.1 inhibition (Fig. 7 B and Table 3). These re-
sults suggest that tyrosines 1761 and 1765 are critical for 
mediating the effects of Vc1.1. Interestingly, these mu-
tants, except the Cav2.3d (Y1765F), also reduced ba-
clofen inhibition of IBa, which indicates that these Y 
residues are also involved in baclofen signaling. We ex-
plored how mutation affects the VI component of inhi-
bition, in the absence and presence of a depolarizing 
prepulse, via baclofen inhibition of IBa through Cav2.3d 
(Y1765F) channels. Experiments were performed with 
either 0.5 or 10 mM EGTA in the intracellular record-
ing solution to (a) identify any effects of intracellular 
divalent cations on IBa facilitation (Zühlke et al., 1999), 
and (b) rule out modulation by phospholipids (Delmas 
et al., 2005) (Fig. S1). The results showed that the effect 
of baclofen was solely mediated by a VI pathway, inde-
pendent of a classical G binding.
We also generated human Cav2.1 (1A-5) (L1852T) and 
Cav2.1 (1A-5) (Q1856E) channel mutants. Remarkably, 
the introduced putative c-Src phosphorylation sites con-
veyed sensitivity to c-Vc1.1 in these channels. Baclofen 
modulation was not affected by the Cav2.1 (L1852T) or 
Cav2.1 (Q1856E) channel mutants (Fig. 7 B and Table 3). 
Collectively, these data suggest that specific c-Src 
phosphorylation sites in the C terminus are needed for 
-conotoxin c-Vc1.1 inhibition of Cav2.3 and Cav2.1 
channels. However, it remains possible that other resi-
dues are also involved in mediating baclofen’s inhibi-
tion of Cav2.3 channels.
D I S C U S S I ON
In this study, we efficiently reconstituted human Cav2.1 
and Cav2.3 channel modulation via human G protein–
coupled GABABRs. Baclofen, a GABABR agonist, inhib-
ited IBa through both channels; however, -conotoxin 
Vc1.1 only inhibited Cav2.3 channels. The effect of 
Vc1.1 on Cav2.3 channels was completely VI and de-
pended on the presence of specific c-Src phosphory-
lation sites in the C terminus of the human 1E (Cav2.3). 
These results define Cav2.3 channels as new targets for 
analgesic -conotoxins.
Cav2 channels and chronic pain
It is well established that Cav2.2 channel inhibition by 
antagonists or via GPCRs produces analgesia in ani-
mals and humans (Altier and Zamponi, 2004). GABABR-
mediated inhibition of Cav2.1 or Cav2.2 channels in 
various neurons is well documented (Cox and Dunlap, 
1992; Mintz and Bean, 1993; Lambert and Wilson, 
1996) and has been shown to involve VD and VI second 
Figure 6. The role of c-Src proteins in GABABR-mediated inhi-
bition by c-Vc1.1 in HEK cells stably expressing human Cav2.3c 
channels and GABABRs. (A) Time course of IBa through Cav2.3c 
channels in the absence (control) and presence of 200 nM c-Vc1.1 
or 50 µM baclofen. Bars indicate c-Vc1.1 or baclofen application. 
Overexpression of wild-type c-Src protein increases the IBa fraction 
inhibited by c-Vc1.1 (top). Overexpression of the double mutant 
c-Src (K295R/Y527F) (middle) or pretreatment with the phos-
phorylated pp60c-Src peptide (50 µM) (bottom) abolishes the ef-
fect of c-Vc1.1 and reduces baclofen inhibition of IBa, respectively. 
Representative current traces (right) are shown at the times indi-
cated by lowercase letters (see Fig.1 B for control). IBa was evoked 
by 150 ms, 0.1-Hz depolarizations to 10 mV, from an HP of 80 mV 
(voltage inset). Peak current amplitudes were plotted as a func-
tion of time. Horizontal dotted lines indicate zero-current 
levels. (B) Average data (±SEM) of IBa inhibition by c-Vc1.1 or 
baclofen after pp60c-Src peptide (50 µM) pretreatment or wild-
type c-Src coexpression in Cav2.1/GABABR or Cav2.3/GABABR 
cells, respectively, or double mutant c-Src (K295R/Y527F) co-
expression in Cav2.3/GABABR cells (*, P < 0.001 vs. controls; one-
way ANOVA). The number of experiments is in parentheses.
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neurons (Matthews et al., 2007), and their inhibition was 
associated with high efficiency opioid therapy without 
tolerance (Yokoyama et al., 2004). Cav2.3 channels are 
ubiquitously expressed in the central and peripheral ner-
vous systems, but their physiological roles and modula-
tion is not well understood. They typically conduct a 
small proportion of whole-cell Ca2+ current and are dif-
ficult to isolate in neurons (Schneider et al., 2013).
Baclofen and -conotoxin Vc1.1 differentially inhibit Cav2.1 
and Cav2.3 channels
Our results demonstrate that baclofen or GABA inhibits 
IBa to a similar extent in Cav2.1/GABABR and Cav2.3/
messenger pathways (Dolphin and Scott, 1986; Diversé-
Pierluissi et al., 1997). We showed that a subset of -
conotoxins, including Vc1.1, also selectively inhibit 
Cav2.2 channels by acting as G protein–coupled GABABR 
agonists (Callaghan et al., 2008; Callaghan and Adams, 
2010; Clark et al., 2010; Daly et al., 2011). This mecha-
nism may help relieve nerve injury–induced neuropathic 
pain (Klimis et al., 2011).
Studies involving pharmacological and genetic ap-
proaches have also established Cav2.3 channels as poten-
tial targets for drugs that treat chronic pain (Saegusa 
et al., 2000; Qian et al., 2013). The anti-nociceptive role 
of Cav2.3 channels was demonstrated in rat dorsal horn 
Figure 7. Kinase-dependent phosphorylation of the intracellular proximal C terminus is needed for VI Cav2.3 channel inhibition by 
c-Vc1.1. (A) Amino acid sequence alignments of e37 regions in splice variants of Cav2.2, Cav2.1, and Cav2.3 and mutant Cav2.1 and Cav2.3 
genes. Y (red), followed by A, E, or T (orange), is shown as a possible substrate for c-Src phosphorylation. (Right) Proposed model for 
c-Vc1.1–induced intracellular signaling leading to Cav2 channel inhibition. Asterisk indicates phosphorylation. (B) Average IBa inhibi-
tion in the presence of 200 nM c-Vc1.1 or 50 µM baclofen in HEK 293T cells transiently cotransfected with wild-type human Cav2.3d 
(1E-d) and Cav2.3c (1E-c); Cav2.1 (1A-5); rabbit Cav2.1 channel subunits; human e37 mutants Cav2.3d (Y1761F), Cav2.3d (Y1765F), 
Cav2.3c (Y1761F), Cav2.3c (Y1765F), Cav2.1 (1A-5) (L1852T), or Cav2.1 (1A-5) (Q1852E); auxiliary human Cav channel subunits 2b-1 
and 3; and human GABABR subunits. Representative normalized IBa traces (current insets) of wild-type or mutant channels are shown 
in the absence (control) or presence of 200 nM c-Vc1.1 or 50 µM baclofen (only 65 ms of the 150-ms current traces are plotted). IBa was 
evoked by depolarizations to +10 mV (Cav2.3c) or 15 mV (Cav2.1), applied at 0.1 Hz from an HP of 80 mV. Dotted lines indicate zero-
current levels. Bar graphs show mean ± SEM; n, number of experiments in parentheses. Labels a, b, and c denote statistically significant 
differences between various mutants and control; NS, not significantly different from wild-type modulation. See Table 3 for statistical 
evaluation of the data.
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time course of IBa activation in the presence of baclofen 
or c-Vc1.1 seemed unaffected. In these cells, c-Vc1.1 did 
not affect the I-V relationship, but baclofen caused a 
hyperpolarizing I-V shift, which suggests that there may 
be an additional signaling mechanism. Our results show 
that neither baclofen nor Vc1.1 elicits VD inhibition of 
Cav2.3 channels via GABABRs. However, it has been 
shown that the rat brain 1Elong splice variant could be 
inhibited in a VD manner via D2 dopamine receptors 
(Page et al., 1998). Our alignment of the human 1E-c or 
1E-d and rat 1Elong splice variants (not depicted) indi-
cate that the N-terminal sequence responsible for VD 
inhibition of rat 1Elong variant is present in human 1E-c 
and 1E-d. Therefore, future experiments should deter-
mine whether or not human Cav2.3 channels can be 
inhibited via D2 receptors in a VD manner. VD modula-
tion may depend on the type of GPCR and specific 
signal transduction mechanism elicited by the GPCR-
specific ligand.
The VI pathway leading to Cav2.3 channel inhibition 
by baclofen or c-Vc1.1 could be disrupted by GDP--S, 
a GDP analogue that keeps G permanently associated 
with G. In all cases, PTX treatment abolished ba-
clofen and c-Vc1.1 inhibition of IBa, indicating that 
GABABRs couple with G proteins of the Gi/Go super-
family in cells expressing Cav2.3 channels (Fig. 5). Anal-
ysis of the VI pathway in Cav2.3/GABABR cells indicated 
that signaling mechanisms that contribute to Cav2.3 
channel inhibition, downstream of G protein subunits, 
involve c-Src kinase activation. For example, wild-type 
c-Src overexpression increased IBa inhibition, whereas the 
dominant-negative double mutant c-Src or the pp60c-Src 
GABABR cells (Figs. 1 and 2). Throughout this study, we 
used cells with similar electrophysiological characteris-
tics and applied supra-maximal doses of baclofen (50 µM) 
or c-Vc1.1 (200 nM) to make sure receptors were fully 
activated and rule out the possibility that differences 
were caused by cell variability.
In Cav2.1 channel–expressing cells, baclofen inhibition 
was VD and could be relieved by a strong depolarizing 
prepulse, reflecting transient dissociation of G protein 
 subunits from the channel. The 20-ms prepulses and 
5-ms interpulses were considered suitable for VD IBa 
relief in Cav2.1 channels (Currie and Fox, 1997). Our 
results on the voltage dependence of inhibition are 
consistent with previous studies demonstrating baclofen 
inhibition of Cav2.1 channels in adrenal chromaffin 
cells and cerebellar Purkinje neurons (Mintz and Bean, 
1993; Currie and Fox, 1997). We did not analyze the 
time course of IBa activation in the presence of baclofen 
or c-Vc1.1 in Cav2.1/GABABR or Cav2.3/GABABR cells. 
However, in Cav2.1/GABABR cells, the time course of IBa 
activation considerably slowed in the presence of ba-
clofen when compared with control. This is a hallmark 
of VD G binding to the 1A (Cav2.1) subunit (Fig. 3 B). 
Interestingly, baclofen only caused a small and statisti-
cally insignificant shift of the I-V and G-V relationships 
in Cav2.1/GABABR cells (Figs. 3 A and 4), which was 
independent of the intracellular EGTA concentration. 
Bourinet et al. (1996) also reported a similar slight posi-
tive shift of the µ opioid receptor–activated Cav2.1 chan-
nel I-V relationship, suggesting possible differences 
between Cav2.1 and Cav2.2 channel–modulating mem-
brane-delimited pathways. In Cav2.3/GABABR cells, the 
TA B l e  3
Summary of IBa inhibition by baclofen and c-Vc1.1 in HEK 293T cells transiently coexpressing GABABRs and Cav2.1 or Cav2.3 channels
Cav2 channel IBa inhibition (%)
c-Vc1.1 (200 nM) Baclofen (50 µM)
Human Cav2.3d 23 ± 2.9 (8) 33.1 ± 1.8 (8)
Human Cav2.3d (Y1761F) 1.7 ± 0.3 (11)a 21.9 ± 1.8 (11)c
Human Cav2.3d (Y1765F) 11.3 ± 3.0 (10)b NS28.9 ± 2.7 (10)
Human Cav2.3c 28.0 ± 4.0 (10) 44.0 ± 3.0 (10)
Human Cav2.3c (Y1761F) 0.37 ± 0.3 (8)a 14.6 ± 1.8 (8)c
Human Cav2.3c (Y1765F) 15.0 ± 3.2 (10)b 28.9 ± 2.7 (10)d
Human Cav2.1 0 (8) 44.4 ± 1.9 (9)
Human Cav2.1 (L1852T) 7.2 ± 1.4 (8)a NS50.6 ± 2.8 (8)
Human Cav2.1 (Q1856E) 6.6 ± 1.7 (8)b NS47.9 ± 3.0 (8)
Rabbit Cav2.1 #20.0 ± 4.0 (7) #50.0 ± 5.0 (8)
Values represent mean ± SEM; n, number of experiments in parentheses. NS, not significantly different from wild-type modulation. One-way ANOVA with 
Bonferroni post-hoc testing was used to test for statistically significant differences except when comparing the effect of c-Vc1.1 on wild-type or mutant 
Cav2.1 (one-way ANOVA on ranks with Tukey test). Data marked with a hash symbol were not included in the statistical analysis. Note that the percentage 
of inhibition with transiently expressed human Cav2.1 or Cav2.3c channels and transiently coexpressed GABABRs (above) is similar (within the statistical 
margin of error) to that obtained with stably expressed human Cav2.1 or Cav2.3c channels in the presence of transiently coexpressed GABABRs (see Table 1).
aP < 0.001 versus Cav2.3d with c-Vc1.1; P < 0.001 versus Cav2.3c with c-Vc1.1; and P = 0.002 versus human Cav2.1 with c-Vc1.1.
bP = 0.003 versus Cav2.3d with c-Vc1.1; P = 0.008 versus Cav2.3c with c-Vc1.1; and P = 0.002 versus human Cav2.1 with c-Vc1.1.
cP = 0.003 versus Cav2.3d with baclofen and P < 0.001 versus Cav2.3c with baclofen.
dP < 0.001 versus Cav2.3c with baclofen.
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generally accepted that the amino acid sequence motif 
around the tyrosine residue and three-dimensional 
structure of the substrate proteins contribute to phos-
phorylation site specificity (Pawson et al., 2001). Our 
structure–function studies confirmed that Y[A/E/T] 
sequences are the likely c-Src phosphorylation substrates 
and represent key switches for the molecular mecha-
nisms involved. The lack of any effect of Vc1.1 on 
human Cav2.1 channels agrees with the absence of a 
c-Src motif in the e37 region and marginal VI compo-
nent in cells expressing these channels. Interestingly, 
c-Src motif Y[K] can also be identified in the Cav2.2[e37a] 
channel, whereas such a motif is absent in Cav2.2[e37b]. 
Therefore, further studies are required to dissect the 
effects of Vc1.1 on Cav2.2 channel splice variants. Our 
results also suggest that the effects of baclofen on 
Cav2.3 channels are, at least partially, controlled by c-Src 
phosphorylation. Given that PTX completely abolishes 
the inhibition by baclofen, an additional PTX-sensitive 
pathway is probably also involved. Future studies should 
be aimed at directly correlating Cav2.3 channel phos-
phorylation and dephosphorylation with inhibition and 
(the absence of) recovery, respectively. Clearly, further 
experiments are also needed to confirm that c-Src ki-
nase directly phosphorylates Cav2.3 channels in vivo.
Therapeutic implications of Cav2.3 channel inhibition
Few studies have examined Cav2.3 (R-type) channel 
modulation in neurons, where a combination of spe-
cific inhibitors is needed to completely block various 
VGCCs while preserving the R-type calcium channel. In 
thalamocortical neurons, R-type current modulation by 
baclofen has been demonstrated and could be antago-
nized by CGP55845 (Guyon and Leresche, 1995). In rat 
DRG neurons, we also observed R-type current inhibi-
tion by baclofen in the presence of specific L-, N- and 
P/Q-type channel blockers (not depicted). However, 
further studies are needed to demonstrate what contri-
bution the R-type current component makes to the 
whole-cell calcium conductance inhibited by Vc1.1 in 
nociceptive neurons.
GABABR activation produces anti-nociceptive effects 
in animal models of acute or chronic pain (Pan et al., 
2008; Bowery, 2010). Baclofen is mainly injected into 
the spine to manage spasticity and neuropathic pain 
and as an adjuvant analgesic for relieving cancer pain 
(Zuniga et al., 2000; Yomiya et al., 2009). Its oral dose 
must be carefully regulated because of possible side ef-
fects. Vc1.1 does not compete with baclofen for bind-
ing to receptors, but it targets the interface between 
the GABABR ectodomains (see Adams and Berecki, 
2013). Vc1.1 was tested in human clinical trials, but its 
development was discontinued because of its lack of 
potency at human 910 nicotinic acetylcholine re-
ceptor, which was proposed to be the molecular target 
(McIntosh et al., 2009). However, with the emergence 
peptide abolished c-Vc1.1 inhibition of IBa (Fig. 6). This 
suggested that Cav2.3 channels are a potential c-Src sub-
strate. It has been demonstrated that certain protein 
tyrosine kinases can be direct effectors of G proteins 
(Bence et al., 1997), and GABA inhibition of Cav2.2 
channels involves direct Go activation of Src kinase 
(Diversé-Pierluissi et al., 1997). However, further stud-
ies are needed to elucidate whether baclofen or Vc1.1 
inhibition of Cav2.3 channels involves direct Gi/Go acti-
vation of c-Src.
In Cav2.1 and Cav2.2 channels, intracellular N and 
C termini and cytoplasmic loops connecting domains 
I–IV have been shown to interact with other proteins 
and are targeted by second messenger pathways, includ-
ing phosphorylation by kinases (Zamponi and Currie, 
2013). Many of these interaction or modulatory sites 
can also be identified in Cav2.3 channels (Schneider 
et al., 2013). Furthermore, alternative splicing, recog-
nized as a mechanism for creating functional diversity 
in VGCCs (Gray et al., 2007), results in a series of Cav2.3 
splice variants (Williams et al., 1994) with similar bio-
physical properties (Pereverzev et al., 2002). Of these, 
Cav2.3c represents the major neuronal type variant, which 
is dominantly expressed in the adult central nervous 
system (Schneider et al., 2013), whereas Cav2.3d, the 
variant cloned from human fetal brain (Schneider et al., 
1994), shows minor in vivo expression in the adult brain 
(Pereverzev et al., 2002). Interestingly, the endocrine 
splice variant Cav2.3e was also identified in nociceptive 
trigeminal ganglion and DRG neurons together with 
Cav2.3a (Fang et al., 2007, 2010). Importantly, the e37 
region containing the putative c-Src phosphorylation 
sites can be identified in all Cav2.3 splice variants.
There is evidence of multiple Src interaction sites in 
various VGCCs. For example, Src interacts with both the 
II–III linker and C-terminal tail regions of the L-type Ca2+ 
channel 1c subunit (Dubuis et al., 2006). c-Src kinases also 
appear to be pre-associated with N-type VGCCs, efficiently 
modulating their function (Schiff et al., 2000). In addi-
tion, c-Src kinases have been implicated in the GABABR-
mediated inhibition of Cav2.2 channels by baclofen 
(Raingo et al., 2007) and Vc1.1 (Callaghan et al., 2008).
To date, GABABR-mediated modulation of Cav2.3 
channels has not been reconstituted in expression sys-
tems, and c-Src phosphorylation of Cav2.3 channels has 
not been demonstrated. Conserved Y residues within 
the e37 region can be identified across all Cav2 family 
members and appear to be key substrates for phosphory-
lation by various tyrosine kinases. Our analysis of the 
e37 regions in Cav2.1 and Cav2.3 channels predicted Src 
kinase motifs in human Cav2.3 channels. These motifs 
were absent in human Cav2.1 (Fig. 7). Although phos-
phorylation site prediction can be error prone, it is a 
useful tool to determine whether e37 regions contain 
sequence contexts typical of c-Src motifs described 
previously in the literature (Amanchy et al., 2007). It is 
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